Ternary Health
GI, Pelvic & Urologic · Interstitial Cystitis / Bladder Pain Syndrome

Interstitial Cystitis / Bladder Pain Syndrome

If you've been treated for UTI after UTI and cultures keep coming back negative — the diagnosis you've been given is not the diagnosis you have.

About Interstitial Cystitis / Bladder Pain Syndrome

What we mean when we say Interstitial Cystitis / Bladder Pain Syndrome.

Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) is a chronic condition characterized by bladder pain, urinary urgency, and frequency in the absence of infection or other identifiable cause. It overwhelmingly affects women and is frequently misdiagnosed as recurrent urinary tract infection.

IC/BPS is heterogeneous. Some patients have Hunner lesions identifiable on cystoscopy; many do not. Pathophysiology involves bladder epithelial dysfunction, mast cell infiltration, neurogenic inflammation, and pelvic floor dysfunction in varying proportions — which is why a single-pathway treatment approach so often fails.

IC/BPS is part of the broader female pelvic-pain cluster. Patients frequently also have endometriosis, MCAS, hEDS, vulvodynia, and IBS. Recognition of the cluster transforms management.

Prevalence

Estimated 3–8 million women and 1–4 million men in the US affected by symptoms consistent with IC/BPS. True confirmed prevalence is lower; under-diagnosis is substantial.

The path to diagnosis

Why Interstitial Cystitis / Bladder Pain Syndrome gets missed.

4–12 million
Estimated US adults with symptoms
RAND Interstitial Cystitis Epidemiology study
Recurrent UTI
Commonly misdiagnosed as
AUA IC/BPS guideline

Interstitial Cystitis / Bladder Pain Syndrome is misdiagnosed routinely — most often as recurrent urinary tract infection — and then mismanaged because the heterogeneity of the condition is rarely characterized. IC/BPS is not one condition; it's several phenotypes that look similar and respond to different treatments.

  1. 01
    Recurrent UTI is the most common misdiagnosis. Patients receive courses of antibiotics for negative or low-count cultures, with no resolution of symptoms. The actual workup that would identify IC/BPS is rarely initiated.
  2. 02
    Hunner lesions on cystoscopy define a distinct subtype with specific treatment implications, but cystoscopy under anesthesia is not always performed. Many patients carry an IC/BPS diagnosis without ever having had the procedure that would phenotype them.
  3. 03
    Embedded UTI, atypical urinary microbiota, and low-count bacteriuria are emerging considerations that standard urine culture misses. Patients with infection-driven symptoms are sometimes labeled IC/BPS without the microbiology being fully characterized.
  4. 04
    The pelvic-pain cluster — endometriosis, MCAS, pelvic floor dysfunction, hEDS — is frequently coexistent. Treating IC/BPS in isolation often produces incomplete responses because the broader picture isn't addressed.
How we approach it

The Ternary Health approach to Interstitial Cystitis / Bladder Pain Syndrome.

01

Phenotype the bladder pain syndrome specifically — Hunner-lesion subtype, mast-cell-driven inflammation, pelvic floor contribution, or embedded-infection pattern — rather than treating all IC/BPS as a single entity.

02

Audit the urinary microbiology workup carefully. Standard urine culture misses embedded UTIs, atypical organisms, and low-count bacteriuria. Where infection-driven symptoms are suspected, expanded microbiology testing matters.

03

Evaluate the pelvic floor and neurogenic components. Manual pelvic floor evaluation, urodynamic findings, and the mast-cell involvement that frequently amplifies bladder symptoms are part of the integrated workup.

04

Map comorbid pelvic-cluster conditions — endometriosis, MCAS, hEDS, vulvodynia, IBS — that frequently coexist with IC/BPS and that change management when identified.

Signals we look for

The Ternary Signal Library for Interstitial Cystitis / Bladder Pain Syndrome.

Our Signal Library for IC/BPS codifies the specific patterns that matter — urologic findings, microbiologic workup, pelvic floor and neurogenic assessment, and pelvic-cluster comorbidities. Your case is mapped against these signals; each present signal is identified and prioritized for your presentation.

Urologic & Cystoscopic Findings
  • Cystoscopy with hydrodistension findings — Hunner lesions present or absent
  • Bladder biopsy results where performed
  • Symptom severity scoring — PUF, ICSI, ICPI patterns
  • Urodynamic findings where indicated
  • Bladder capacity and compliance documentation
Microbiologic & Embedded-Infection Workup
  • Standard urine culture history and patterns
  • Expanded microbiology — Microgen DX, NextGen sequencing where pursued
  • Low-count bacteriuria and clinically significant thresholds
  • Embedded UTI considerations and biofilm-targeted protocols
  • Mycoplasma, Ureaplasma, and atypical organism testing
Pelvic Floor & Neurogenic Assessment
  • Manual pelvic floor evaluation findings
  • Pelvic floor PT history and response patterns
  • Pudendal nerve involvement screening
  • Voiding dysfunction and urgency pattern characterization
  • Sexual dysfunction and dyspareunia patterns
Comorbid Pelvic & Mast Cell Patterns
  • Endometriosis screening and workup status
  • MCAS evaluation — mast-cell-driven bladder inflammation pattern
  • Hypermobility — Beighton score and connective tissue findings
  • Vulvodynia and related pain syndromes
  • IBS and GI dysmotility overlap
The nine-stage workflow, applied

How a Interstitial Cystitis / Bladder Pain Syndrome case moves through our workflow.

Our nine-stage workflow is the same for every engagement. What changes per condition is the content at each stage — the records we pull, the signals we apply, the specialists we map, the pathways we evaluate. Below, how your case specifically would move through each stage.

Stage 01 · 0–2
Qualification
Fit screen confirms IC/BPS diagnosis or strongly consistent presentation, access to urologic workup and culture history, and current treatment status. Symptom severity and treatment trajectory matter for case prioritization.
Stage 02 · 3–7
Intake & data aggregation
Records pull emphasizes cystoscopy reports, urine culture history, pelvic imaging if performed, prior treatments, and pelvic floor PT history. Symptom pattern and flare-trigger timeline reconstructed.
Stage 03 · 7–10
Case structuring
Case schema populated. Bladder phenotype characterized — Hunner versus non-Hunner. Comorbid pelvic-cluster screening initiated in parallel. Embedded infection considerations evaluated against history.
Stage 04 · 10–14
Signal analysis
The Ternary Signal Library for IC/BPS is applied. Typical case activates 12–18 signals across urologic, microbiologic, pelvic floor, and comorbidity domains. Each signal evaluated for your specific presentation.
Stage 05 · 14–18
Evidence retrieval
Literature scan emphasizes AUA IC/BPS guidelines, Hunner lesion-specific treatment evidence, expanded microbiology and embedded UTI literature, and the pelvic-cluster comorbidity research. Condition-specific Evidence Matrix refreshed.
Stage 06 · 18–22
Pathway mapping
Pathway map built across IC/BPS-experienced urology, pelvic floor PT, urogynecology where pelvic-cluster comorbidities indicated, and where applicable mast cell allergy/immunology. Specialists mapped from our Specialist Graph.
Stage 07 · 22–26
Synthesis & plan construction
Every option weighed against the three questions (Evidence × Personalization × Action), then prioritized and sequenced. Dependencies encoded as a directed graph — phenotype identification informs treatment selection, infection workup resolution informs antibiotic versus IC-directed therapy, pelvic floor and comorbidity findings inform integrated management.
Stage 08 · 26–30
Delivery & calibration
Findings call with attention to phenotype-specific treatment sequencing, pelvic floor and comorbidity priorities, and procedural decision support. Your priorities and constraints update the plan before finalization.
Stage 09 · 30–60
Execution support
30 days of asynchronous follow-up through the typical IC/BPS consultation sequence — urology, pelvic floor PT, and any indicated comorbid specialist consultations. Outcomes captured into the Ledger.
Deliverables

What you receive.

  • A written case synthesis characterizing the specific bladder phenotype in your case
  • Integration of cystoscopy, microbiology, pelvic floor, and comorbidity findings into a single view
  • Expanded microbiology audit for embedded UTI and atypical organism considerations
  • Pelvic-cluster comorbidity workup recommendations across endometriosis, MCAS, hEDS, vulvodynia
  • Treatment decision framework calibrated to your phenotype — intravesical, oral, procedural
  • Specialist identification for IC/BPS-experienced urology, pelvic floor PT, and comorbidity workups
  • A written action plan and follow-up support as you implement it
What a Ternary report adds

What a Precision Deep Dive provides for Interstitial Cystitis / Bladder Pain Syndrome.

A Ternary Health Precision Deep Dive for IC/BPS characterizes the bladder pain phenotype, evaluates mast cell and connective tissue contributions, audits the urinary microbiology workup including embedded and atypical infections, reviews the pelvic floor and neurogenic components, and synthesizes the evidence on intravesical, oral, and procedural therapies.

See the published sample reports · read the Ternary Method

Frequently coexisting conditions

What we look for alongside Interstitial Cystitis / Bladder Pain Syndrome.

Patients with Interstitial Cystitis / Bladder Pain Syndrome frequently present with one or more of the following. Ternary reports evaluate the full picture rather than the condition in isolation.

Common questions — Interstitial Cystitis / Bladder Pain Syndrome

What prospective Interstitial Cystitis / Bladder Pain Syndrome clients ask most.

I've been told I have IC but my cultures keep coming back negative. Could it still be infection?
Possibly. Standard urine culture misses embedded UTIs, low-count bacteriuria, and several atypical organisms. The literature on expanded microbiology — Microgen DX, next-generation sequencing — has matured significantly, and a subset of patients labeled IC/BPS have infection-driven symptoms that respond to targeted antibiotic strategies. The Ternary report evaluates whether expanded microbiology is appropriate for your case.
Do I have Hunner lesions?
Cystoscopy under anesthesia is the only way to know. Roughly 10 to 15 percent of IC/BPS patients have Hunner lesions, and the subtype responds to specific treatments — including fulguration and steroid injection — that don't apply to non-Hunner disease. If you've never had cystoscopy under anesthesia, that's often the highest-leverage next step. We build that into the plan.
Does pelvic floor PT actually help?
For many patients, yes — particularly those with pelvic floor hypertonicity as a major component. The literature supports it as part of multimodal management. The challenge is finding a PT with specific IC/BPS and pelvic floor expertise. We map qualified providers in the report.
Do I need a confirmed diagnosis before applying?
An IC/BPS diagnosis or a strongly consistent presentation is preferred. If you've been treated for recurrent UTI without resolution and IC/BPS hasn't been formally considered, we can frame the differential and the evaluation pathway.
What about the other pelvic conditions?
Screened in every case. Endometriosis, MCAS, hEDS, vulvodynia, and IBS frequently coexist with IC/BPS, and integrated management produces meaningfully better outcomes than treating each in isolation. The Ternary report builds the integrated picture.
Working through this on your own?

Three ways to engage Ternary on Interstitial Cystitis / Bladder Pain Syndrome.

From a free starting point to a full personalized action plan — three tiers, one methodology, all tailored to Interstitial Cystitis / Bladder Pain Syndrome.

Start exploring

Free Brief

$0

A 3–5 page personalized starting point on your condition. Most relevant labs, specialist categories, first decisions worth pursuing. No charge.

Generated instantly, no charge.

Get a free Brief
Get organized

Launchpad

$400

A research-based preparedness guide. Current literature, realistic prognosis, test and treatment categories worth exploring, and a checklist of what you might consider to better manage and understand your condition.

Delivered in 3–5 business days

Start a Launchpad
Get answers

Precision Deep Dive

$6,500

A vigorously researched and highly personalized action plan: the specialists and centers of excellence worth considering, evidence-graded options, and a prioritized set of questions to raise — all curated for your specific condition and lifestyle, for you and your physicians to weigh together. The plan includes 30 days of follow-up support and tailored insights into how best to navigate your situation now and in the future.

September 2026 cohort

Apply for a Deep Dive
What a Ternary report looks like

See exactly what you receive.

A composite sample illustrating the structure and depth of every Ternary Health Precision Deep Dive. Same universal 17-section format used for Interstitial Cystitis / Bladder Pain Syndrome — drawn from four research-validated patient profiles across four conditions.

Every Ternary engagement produces a report with the same architecture: client profile, applied methodology, signal analysis, lab and genetic findings, imaging synthesis, disease model, intervention prioritization, specialist pathway, staged medical therapy, 90-day roadmap, and monitoring cadence. The composite shows you exactly how that architecture renders.

Ready for clarity on your Interstitial Cystitis / Bladder Pain Syndrome?

Applications for the September 2026 cohort are open now and reviewed in the order received. Not ready? A free Ternary Brief on Interstitial Cystitis / Bladder Pain Syndrome is generated instantly, no charge.